These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15650025)

  • 1. Cancer promoted by the oncoprotein v-ErbA may be due to subcellular mislocalization of nuclear receptors.
    Bonamy GM; Guiochon-Mantel A; Allison LA
    Mol Endocrinol; 2005 May; 19(5):1213-30. PubMed ID: 15650025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear export of the oncoprotein v-ErbA is mediated by acquisition of a viral nuclear export sequence.
    DeLong LJ; Bonamy GM; Fink EN; Allison LA
    J Biol Chem; 2004 Apr; 279(15):15356-67. PubMed ID: 14729678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequences required for the transition from monomeric to homodimeric forms of thyroid hormone receptor alpha and v-erbA.
    Zubkova I; Subauste JS
    Mol Cell Endocrinol; 2003 Jan; 199(1-2):61-72. PubMed ID: 12581880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway.
    Urnov FD; Yee J; Sachs L; Collingwood TN; Bauer A; Beug H; Shi YB; Wolffe AP
    EMBO J; 2000 Aug; 19(15):4074-90. PubMed ID: 10921888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemic transformation by the v-ErbA oncoprotein entails constitutive binding to and repression of an erythroid enhancer in vivo.
    Ciana P; Braliou GG; Demay FG; von Lindern M; Barettino D; Beug H; Stunnenberg HG
    EMBO J; 1998 Dec; 17(24):7382-94. PubMed ID: 9857194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirements for repression of retinoid X receptor by the oncoprotein P75gag-v-erbA and the thyroid hormone receptors.
    Wahlström GM; Vennström B
    Mol Endocrinol; 1998 May; 12(5):645-53. PubMed ID: 9605927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The v-ErbA oncoprotein quenches the activity of an erythroid-specific enhancer.
    Braliou GG; Ciana P; Klaassen W; Gandrillon O; Stunnenberg HG
    Oncogene; 2001 Feb; 20(7):775-87. PubMed ID: 11314012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recruitment of the oncoprotein v-ErbA to aggresomes.
    Bondzi C; Brunner AM; Munyikwa MR; Connor CD; Simmons AN; Stephens SL; Belt PA; Roggero VR; Mavinakere MS; Hinton SD; Allison LA
    Mol Cell Endocrinol; 2011 Jan; 332(1-2):196-212. PubMed ID: 21075170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The thyroid hormone receptor functions as a ligand-operated developmental switch between proliferation and differentiation of erythroid progenitors.
    Bauer A; Mikulits W; Lagger G; Stengl G; Brosch G; Beug H
    EMBO J; 1998 Aug; 17(15):4291-303. PubMed ID: 9687498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the DNA-binding and dominant negative activity of v-erbA homodimers.
    Subauste JS; Koenig RJ
    Mol Endocrinol; 1998 Sep; 12(9):1380-92. PubMed ID: 9731706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncoprotein P75gag-v-erbA represses thyroid hormone induced transcription only via response elements containing palindromic half-sites.
    Wahlström GM; Harbers M; Vennström B
    Oncogene; 1996 Aug; 13(4):843-52. PubMed ID: 8761306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimerization of v-erbA on inverted repeats.
    Zubkova I; Subauste JS
    Biochem Biophys Res Commun; 2002 May; 294(1):35-41. PubMed ID: 12054736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A choice between transcriptional enhancement and repression by the v-erbA oncoprotein governed by one nucleotide in a thyroid hormone responsive half site.
    Andersson ML; Vennström B
    Oncogene; 2000 Jul; 19(32):3563-9. PubMed ID: 10951561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. V-erbA requires auxiliary proteins for dominant negative activity.
    Hermann T; Hoffmann B; Piedrafita FJ; Zhang XK; Pfahl M
    Oncogene; 1993 Jan; 8(1):55-65. PubMed ID: 8093812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. V-erba homodimers mediate the potent dominant negative activity of v-erba on everted repeats.
    Zubkova I; Subauste JS
    Mol Biol Rep; 2004 Jun; 31(2):131-7. PubMed ID: 15293789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of transformation by v-ErbA: substitution for steroid hormone receptor function in self renewal induction.
    Bauer A; Ulrich E; Andersson M; Beug H; von Lindern M
    Oncogene; 1997 Aug; 15(6):701-15. PubMed ID: 9264411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The v-erbA oncogene (review).
    Thormeyer D; Baniahmad A
    Int J Mol Med; 1999 Oct; 4(4):351-8. PubMed ID: 10493974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimerization interfaces of v-erbA homodimers and heterodimers with retinoid X receptor alpha.
    Shen Q; Subauste JS
    J Biol Chem; 2000 Dec; 275(52):41018-27. PubMed ID: 11018031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid hormone receptor, v-ErbA, and chromatin.
    Wolffe AP; Collingwood TN; Li Q; Yee J; Urnov F; Shi YB
    Vitam Horm; 2000; 58():449-92. PubMed ID: 10668407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the DNA binding specificity and function of v-ErbA and thyroid hormone receptor alpha 1.
    Subauste JS; Koenig RJ
    J Biol Chem; 1995 Apr; 270(14):7957-62. PubMed ID: 7713893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.